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Summary
Background Dendritic cells (DC) are the most potent antigen-presenting cells (APC)
and stimulators of T cells. Dendritic cells are also likely to be essential for the initiation
of allergic immune responses in the lung. However, there are not many data on the
presence of dendritic cells in the airways of patients with atopic asthma and on the
effects of corticosteroid-treatment on such dendritic cells.
Objective We investigated the distribution of dendritic cells in the bronchial epithelium
and mucosa of 16 non-smoking atopic asthmatic patients and eight healthy control
subjects using detailed immunohistochemistry (CDla, HLA-DR, L25 as markers for
dendritic cells).
Methods Eleven asthmatics were treated for 2.5 years with bronchodilators only and
five with bronchodilators and inhaled beclomethasone dipropionate (BDP), 800^g
daily. The patients were randomly sampled from a double-blind multicentre study.
Re.sulis There were higher numbers of CDla ' DC ( P - 0.003). L25"^  DC ( Z' - 0.002)
and HLA-DR expression {P = 0.042) in the bronchial mucosa of asthmatic patients
compared with healthy controls. After 2.5 years of treatment, we found a significant
increase in fiow expiratory volume in I second (FEV,) (P = 0.009) and a significant
decrease in hyperresponsiveness (PC^i histamine) (/" = 0.013) in the corticosteroid
group {n = 5) compared with the bronchodilator group (« ^  11). This dinical improve-
ment in the corticosteroid-treated group was accompanied by significantly lower
numbers of CDla^ DC (i* = 0.008), and HLA-DR expression (/*-0.028) in the
bronchial mucosa than in the bronchodilator-treated group.
Conclusion Our data suggest that dendritic cells are involved in asthmatic inflammation
and that corticosteroids may downregulute the number of dendritic.
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I . . . . mediated inflammatory process in the airways [1-3].
Antigen-presenting cells (APC) play an essential role in
Atopic asthma is associated with a chronic T-cell- asthma since T lymphocytes cannot respond to antigens
Corrcspondetice: Dr G.M. Moller. Deparlmetit of Imm.nology. without the help of APC [4]. Dendritic cells (DC) are the
Erasmus University. PO Box 1738, 3000 DR Rotterdam. The Nether- "lOSt potent APC and in contrast tO other APC unique in
lands. their capacity to stimulate naive T cells [5,6]. Therefore,
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they may play a key role in the initiation of immune
responses. In the lung, dendritic cells are predominantly
observed in epithelial and subcpithelial tissue of the
bronch(iol)us and in the bronchus-associated lymphoid
tissue [7]. Typical immunohistological features of DC are
a strong major histocompatibility complex (MHC) class
II(HLA-DR) expression [8-10], long cytoplasmic exten-
sions, and the absence or a juxtanuclear spot of acid
phosphatasc. A combination of dendritic morphology
and the expression of CDla is characteristic for DC
[11.12]. Increased numbers of CDla ' DC and increased
expression of MHC class II have been described in
bronchial biopsies of asthmatic patients [13].
Corticosteroids arc the most effective therapy for
asthtna, bul their precise mechanism of action is still
unclear [14]. Corticosteroids inhibit cytokine gene tran-
scription and cytokine effects, thereby reducing chronic
inflammation in asthma [14-17]. To date, the effects of
inhaled corticosteroids on DC in asthma are unknown.
We hypothesized that the beneficial effects of corticos-
teroid therapy in atopic asthmatics may in part result
from a downregulation of the numbers of DC. resulting
in a decreased local T-ccll stimulation. Therefore we
examined the distribution of the DC in the bronchial
epithelium and mucosa of atopic asthmatics by immu-
nohistochemistry. To this aim the effects of 2.5 years of
double-blind treatment with bronchodilators alone or
with bronchodilators plus beclomethasone dipropionate
(BDP) were evaluated. The patients were randomly
sampled from the Dutch chronic non-specific lung dis-
ease (CNSLD) study [18].
Materials and methods
Patients and control subjects
Sixteen non-smoking atopic asthmatic patients (seven
women, nine men. median age 43 years, range 24-61
years) were randomly sampled from the Dutch CNSLD
study group [ 18.19] in two participating centres. Gronin-
gcn and Rotterdam.
The diagnosis of asthma was based on a history of
attacks of breathiessness and wheezing without chronic
cough or sputum production (i.e. for more than 3 months
per year),according to the criteria of the American
Thoracic Society [20]. Atopy was defined as a positive
skin-prick test to house dust mite or at least two of 12
common aeroallergens (mean weal size > 0.7 times the
histamine weal size [21]). All patients showed airway
hyperreactivity to histamine with a provocative
concentration of histamine causing a 20% decrease in
FEVi (PC.,,) of ^ 8tng/mL [19.21]. Patients were trea-
ted in a double-blind fashion with an inhaled /i2-agonist
(terbutaline, 250 //g two puffs) plus either inhaled corti-
costeroid (BDP. 100//g two puffs) (BA + CS)(« = 5), an
anticholinergic bronchodilator (ipratropium bromide,
20 //g two puffs) (B A + AC)(« - 5) or placebo
(BA +PL)(/;==6). All medication was taken four times
daily. Because no significant differences were found
between the BA + AC group atid the BA + PL group
with regard to FEV| and PC211 the data were subse-
quently pooled for analysis in one bronchodilator
group («^11). The fibreoptic bronchoscopy was per-
formed at the end of the 2.5 years study in the same
period (between August and December) in both centres,
before breaking the code. Eight healthy non-smoking
subjects (three women, five men. median age 23 years,
range 19-52 years) without medication were studied as
controls. All controls had a PC20 of more than 8 mg/tnL
and a median FEV, of 103 (88- 110) % predicted. Patient
and control characteristics arc shown in Table 1. Further
details of the study methods have been described pre-
viously [19]. The study protocol was approved by the
Medical Ethics Committee; all patients and controls gave
written informed consent.
Bronchoscopy
Fibreoptic bronchoscopy ( Olympus model BF IT 10,
Tokyo, Japan) was performed with atropine 0.5 mg
intramuscularly as premedication. Terbutaline, two
puffs of 250//g per Nebuhaler, was given 30 min before
the procedure. The nose, throat and vocal cords were
anaesthetized with topical lidocaine spray. An Olympus
alligator forceps model FBI5C and the fenestrated for-
ceps model FBI9C were used to take two biopsies from
segmental and subsegmental divisions of the main
bronchi.
Bronchial biopsies
Each biopsy was immediately placed in isotonic saline
and frozen within 20 min in Tissue-Tek II OCT embed-
ding medium (Miles., Naperville. Illinois. USA). Samples
were stored at -80"C until use. Frozen sections (6/fm)
were cut on a Reichert-Jung 2800 Frigocut cryostat. Two
sections from each biopsy were placed on poly-L-Iysine-
coated (Sigma Diagnostics. St Louis. MO. USA) micro-
scopic slides. Sections were air dried for 30 min and
stored at -8O'C until use.
Immunoh istodwmistry •
The following monoclonal antibodies (MoAb) were
used: OKT6 (CDla) (American Type Culture Collection.,
Rockville. Maryland, USA), directed against the CDla
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Table 1. Patient and control subject characteristics
Paliciu
no. Sex
Corticosteroici group
I
2
3
4
5
F
M
F
F
F
Age (year)
32
61
44
60
45
Baseline FEV,
% predicted
51.8
84.0
75.0
59.7
49.2
After 2.5 years
FEV|
% predicted
56.4
98.7
88.5
90.3
69.6
Baseline PC20
mg/mL
0.17
0.94
0.06
0.06
0.05
After 2.5 years
PC20
mg/mL
0.10
5.38
0.45
0.96
0.21
Median
Bronchodilator group
45 59.7
1
2
3
4
5
6
7
8
9
10
U
Median
Control subjects
1
2
3
4
5
6
7
8
M
M
F
M
M
M
M
F
M
M
F
M
M
M
F
F
M
M
F
32
38
43
44
24
50
57
30
26
42
38
38
19
23
23
24
23
23
52
35
70.4
48.6
54.3
63.5
61.5
65.1
81.6
100.0
38.3
48.7
57.0
61.5
102
109
109
103
96
88
88
110
88.5
51.7
31.2
53.4
66.3
54.7
62.7
42.3
96.4
60.0
56.5
43.6
54.7
0.06
0.79
0.03
0.03
0.02
0.19
0.28
0.14
4.72
0.24
0.24
0.13
0.19
0.45
0.13
0.01
0.04
0.05
0.58
0.18
0.04
0.42
0.40
0.87
0.06
0.13
Median 23 103
antigen of DC [ 12]; L25, a MoAb directed against B cells
and DC [13] was kindly provided by Dr T. Takami
(Gifu, Japan); HLA-DR ( Central Laboratory of the
Netherlands Red Cross Blood Transfusion Service
(CLB), Amsterdam, the Netherlands), and biotin-con-
jugated HLA-DR MoAb (Becton Dickinson, San Jose,
CA, USA). The MoAb staining was detected by the
immuno-alkaline phosphatase anti-alkaline phosphatase
(APAAP) method. The sections were fixed in acetone
for 10 min at 20°C, rinsed in phosphate-buffered saline
(PBS. pH 7.2) and placed in a half-automatic stainer
(Shandon, Pittsburgh, PA. USA). In this stainer the
slides were sequentially incubated with bovine serum
albumin (BSA) 2% in PBS for lOmin, incubated with
normal rabbit serum (CLB, Amsterdam, the Nether-
lands) for 10 min and incubated with the MoAb in the
optimal dilution for 30 min at 2O''C. The optimal
dilutions were determined by previous titration studies
of the specific MoAb (0KT6 10 //g/mL; L25 I ^g/mL
and HLA-DR 0.1 /.(g/mL). The sections were subsequently
rinsed in PBS for 5 min and incubated for 30 tnin with a
rabbit anti-mouse (RaM) (1:20) immunoglobulin anti-
serum, rinsed in PBS, incubated with APAAP (1:40)
(Dakopatts, Glostrup, Denmark) for 30 min at 20°C,
rinsed in PBS and TRIS buffer (pH 8.0), and incubated
for 30 min with New Fuchsin substrate (Chroma, Stutt-
gart, Germany), which stained positive cells red. Finally,
the sections were rinsed with distilled water, counter-
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stained with Mayer's haematoxylin, and mounted in
glycerin gelatin. Control staining was performed by
substitution with PBS and incubation with an irrele-
vant MoAb of the same isotype and concentration.
To establish that L25 ^ DC were also expressing HLA-
DR we performed a double-labelling with L25 and
biotinylated HLA-DR. The procedure followed the
APAAP protocol up to the incubation with APAAP
for 30 min. After rinsing in PBS and blocking with
normal mouse serum (1 : 10) for lOmin, the slides were
incubated for 45 min with the second MoAb biotinylated
HLA-DR. Slides were rinsed in PBS and incubated with
streptavidine-/? galactosidase (Biogenex, San Ramon,
CA, USA) for 45 min. and rinsed again with PBS.
Slides were sequentially incubated with (i galactoside
(Serva. Heidelberg. Germany) which stained positive
cells green, rinsed in TRIS buffer {pH 8.0) and stained
with New Fuchsin, which stained L25 * cells red. Finally,
the sections were rinsed in distilled water and mounted in
glycerin gelatin. The immuno-double staining with L25
and HLA-DR was performed on three sections of three
different patients, because of scarcity of biopsy material.
Quantification
Biopsies were coded and two sections 120 //m apart were
counted in a blinded fashion for each antibody and each
biopsy at a magnification of 10x40 by one person
(G.M.M.) and the mean value was calculated. With an
eye piece graticule the numbers of positively stained cells
were counted in a zone 100//m deep in the bronchial
mucosa along the length of the epithelial basement
membrane (BM), which had to be covered with epithe-
lium over at least 500//m. Cells were counted if they
stained red and contained a nucleus. The cell counts were
expressed as the number per unit (1 mm) of basement
membrane. The (biotinylated) HLA-DR expression was
scored semiquantitatively on a 0 3 scale (0 = negative;
l=weak; 2 = strong; 3 ^ very strong). Double-stained
cells L25 * and biotinylated HLA-DR^ were counted
if they stained violet and contained a nucleus.
Statistical analysis
The numbers of positive cells for most of the MoAb used
showed a positive skewed distribution and therefore were
analysed using non-parametric statistics. Median cell
counts from biopsies from asthmatics who received
inhaled corticosteroids were compared with those who
received only bronchodilators using the Mann-Whitney
t/-test. Median cell counts from biopsies from atopic
asthmatics of the bronchodilator group were compared
with median cell counts of the control subjects using the
Table 2. Pulmonary function data of the patients included in
the study
Corticosteroid
group
Bronchodilator
group -value
AFEV, 14.7 (4.6-30.6) -3.6 (-39.3-21.7) 0.009
2.5 (-0.8-4.0) 0.6 (-3.5-1.9) 0.013
AFEVi in % predicted: difference in median change (ranges) of
FEV| % predicted from baseline to 2-5 years.
Alog^PC^o in mg/mL: difference in median change (ranges) of
logiPCio mg/mL to histamine from baseline lo 2.5 years.
Mann-Whitney L'-test. A value of F< 0.05 was consid-
ered significant.
Results
Pulmonary function data
Details of patient and pulmonary function data have
been described before [18]. In short: 2^  years of inhaled
BDP resulted in a significant improvement in FEV| of
14.7% of predicted compared with bronchodilator group
(-3.6% of predicted. P-0.009) (Table 2). Log2PC2o in
the corticosteroid group improved 2.5 dose steps, com-
pared with 0.6 dose steps in the bronchodilator group
(/' = O.OI3)(Table2).
Bronchial epithelium
Some sections could not quantitatively be evaluated for
bronchial epithelial infiltration because they did not
show enough intact epithelium (Table 3). In the sections
of the asthmatic patients who received bronchodilators
only {n = l) the epithelitim consisted for approximately
60Vo of a monolayer and for 10% of a multilayer of
partially stratified cuboidal epithelium; the epithelium of
the group of corticosteroid-treated patients consisted for
approximately 45% of a monolayer and for 40% of a
multilayer of cuboidal epithelium. The loss of epithelium
from the BM (shedding) was 30% of the total length of
epithelium in the bronchodilator group whereas it was
15% in the corticosteroid group.
Though there were clearly dendritic-shaped CDla^
cells expressing MHC class II in the epithelium of all the
groups studied, differences between groups did not reach
statistical significance (Table 3).
Bronchial mucosa
The bronchial mucosa of the asthmatic patients con-
sisted of a subepithelial cell-rich layer and a deeper cell
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Table 3. MediLin LXII counts (ranges) in bronchial epithelium and mucosa in atopic asthmatics after 2.5 yrs treatment and in control
stihjects per mm of basement mcmbriine
Corticosteroid group Bronchodilator group Control subjects
0 (0-3.6)
1.0(0-3.2)ill
0 (0-4.0)
0.5(0-1.7)
n - 5
1.5(1.0-2.0)
*P-valuc
0.106
0.461
0.594
0.008
0.282
0.028
*/•-value
0.601
1
0.635
0.003
0.002
0.042
Bronchial epithelium
C D l a ' D C
L25" ceils
HLA-DR
Bronchial mucosa
CDla ^ DC
L25 ' cells
HLA-DR
0(0)
n = 4
2.5(0-10.4)
0(0-3.0)
fi = 5
0.7(0-1.4)
H = 4
5.7(1.6-16.3)
1.0(0-2.0)
n = 5
0.4 (0-5.3)
/ j = I O
0.5 (0-9.6)
1 (0-2.0)
n=\0
2.5(1.1-6.7)
n=10
10.3(6.7-13.6)
2.0 (0-3.0)
/!=IO
tMedian score (ranges).
'P Corticosteroid group compared with bronchodilator group.
P Broncbodilator group compared with controls.
poor layer. Higher numbers of C D l a ' DC were found in
the bronchial mucosa of patients of the bronchodilator
group (F^0.008) (Fig. I). In addition, the numbers of
L25 ' cells (Figs 1 and 2) and the expression of MHC
class II (Fig. 1) in the bronchodilator group were higher
than in the heahhy controls (Table 3). The double-
staining of HLA-DR and L25 showed that virtually all
L25 ' DC expressed HLA-DR. The HLA-DR expres-
sion was not only confined to cells in the mucosa showing
an irregular outline with marked cytoplasmic extensions
(DC), but there were also other cells like lymphocytes
and macrophages positive for HLA-DR.
The numbers of CDla ' DC were significantly lower in
the corticosteroid-treated group than in the bronchodi-
lator group (Z'-0.008) (Fig. 1). The number of L25^
cells in the corticosteroid group was also lower (median
5.7/mmBM) than in the bronchodilator group (median
10.3/mmBM), but this difference did not reach signifi-
cance (P = 0.282) (Table 3). However, a significantly
lower MHC class 11 expression was found in the corti-
costeroid group compared with the bronchodilator
group (Fig. l ) ( / ' = 0.028).
Discu^ion
In this study we have observed that the numbers of DC in
the bronchial mucosa of atopic asthmatic patients are
significantly higher than in healthy control subjects and
that 2.5 years of inhaled corticosteroid therapy down-
regulate the number of DC to normal levels, accompa-
nied by a significantly improved FEV| and reduced
hyperresponsiveness.
Our data of increased numbers of CD la"*" DC in atopic
asthma are in agreement with data of a study of Bellini et
al. [22] who also showed increased numbers of intra-
epithelial and mucosal CDla ' DC in atopic asthmatics
as compared to non-asthmatic atopic controls sensitized
to the same allergen. Furthermore, an increased frequency
of DC has been reported in the nasal mucosa of patients
with atopic rhinitis during the pollen season [23].
Dendritic cells in the epithelium of the airways form a
network [24,25]. For primary responses they are strate-
gically positioned to pick up inhaled antigens, migrate to
regional lymph nodes and present the inhaled antigens to
lymphnode T cells. For secondary responses in the
mucosa local antigen presentation by DC to T cells
and local activation of T cells are thought to occur as
well [26]. In asthma it has been suggested that DC play a
prime role in inducing cytokine production by the local
activation of T cells [27.28]. In this way they are thought
to act as important pro-inflammatory cells. It has indeed
been demonstrated both //; vivo [29] as well as in vitro
[22.30] that DC are able to activate TH. cells. The
mechanisms by which DC induce the expansion of THi
cells are still unclear, but some consider — despite the
low production of cytokines by DC — the secretion of
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interleukin-1, a co-stimulator for THT cells, as impor-
tant. DC might, however, also induce TH| expansion
[31]. In vitro IL-12 production by DC favours such TH-1
expansion, as observed by secretion of interferon-gamma
(IFN7) and immunoglobulin G a^ (IgG^a) humoral
responses [32].
Biopsy studies in patients with asthma have confirmed
that inhaled corticosteroids reduce the number and
activation of several inflammatory cells [33-36].
Although this study was carried out on a limited
number of patients, our data show that clinical improve-
ment induced by local BDP administration is accompa-
nied by significantly lower numbers of CDla^ DC and
HLA-DR^ cells in the bronchial mucosa. The here
described inhibitory effects of 2.5 years of corticosteroids
on DC numbers and HLA-DR expression, are in agree-
ment with data of Burke ct al. who described a reduction
in RFDl ^ DC and HLA-DR expression after 3 months
of budesonide in asthma [13]. Thus, long-term treatment
with inhaled corticosteroids also reduces the number of
DC in the bronchial mucosa. Studies in the nasal mucosa
of patients with atopic rhinitis showed that 3 months of
fluticasone therapy decreases the CDla"^ and HLA-
DR^ cells [37].
It may be that chemoattractive factors such as leuko-
triene B4 [38], monocyte chemoat tract ant protein 1 [39],
and substance P play a role in attracting DC into the
epithelium in allergic inflammation. Substance P,
secreted by C-fibres was found to be a highly effective
chemoattractant for DC [40] and in this way neurogetiic
inflammation might contribute to the DC migration.
Interestingly, corticosteroids have been reported to
suppress the release of chemotactic factors from
epithelial cells, indicating a possible important role
of the epithelium in DC kinetics [38] under such
circumstances.
In conclusion, our data show that DC numbers are
elevated in atopic asthma, and can be normalized by
local corticosteroid therapy. We suggest that DC may
play an important role in the initiation and propagation
of the asthmatic inflammation because DC are situated
strategically in bronchial mucosa and DC have been
described as the most potent APC population for T-cell
stimulation. In this way, reduction of DC numbers after
2.5 years of corticosteroid therapy may result in a down-
Fig. 1. Individual counts for cells expressing (a) CDla"*" DC
and (b) L25"^  DC in the bronchial mucosa, expressed as the
number of positive cells/mm basement membrane and indivi-
dual score of (c) HLA-DR expression in the bronchial mucosa.
Median values are represented by the horizontal bars. • .
Corticosteroid. O. Bronchodilator. D Control subjects.
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Fig. 2. Cryostat section of a bronchial mucosal biopsy of an
iisthmatic patient. L25 ' dendritic-shaped cells in the bronchial
epithelium and mucosa. situated just under the BM (arrows).
regulation of T-cel! activation and hence affect allergic
airway inflammation.
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